Cellgram DC
Alternative Names: Autologous dendritic cells vaccine - Pharmicell; Cellgram-DC; Cellgram-DC-PCLatest Information Update: 28 Jan 2024
At a glance
- Originator Pharmicell
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ovarian cancer
- No development reported Pancreatic cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer in South Korea (SC, Injection)
- 29 Dec 2022 Pharmicell terminates a phase I trial in Pancreatic cancer in South Korea (SC, Injection) due to difficulty in recruitment (NCT04615845)
- 29 Dec 2022 Pharmicell terminates a phase I trial in Ovarian cancer (Late-stage disease, Recurrent, Second-line therapy or greater, In adults, In the elderly) in South Korea (SC, Injection) due to difficulty in recruitment (NCT04614051)